Literature DB >> 10516910

Epidemiology and risk factors for nosocomial pneumonia. Emphasis on prevention.

M H Kollef1.   

Abstract

UNLABELLED: VAP is a complex nosocomial infection, the disease expression and resulting patient outcome of which is dependent on host factors, the causative organism, the timing and adequacy of treatment, and the presence of intrinsic or inducible antibiotic resistance. Significant improvements have been achieved in our ability to reduce the occurrence of VAP in the hospital setting. Clinicians caring for mechanically ventilated patients should strive to develop focused programs for the prevention of VAP, other nosocomial infections, and the occurrence of antibiotic-resistant infections at their institutions. The benefits of such programs are well demonstrated. The components of a PDSA (Plan-Do-STUDY-Act) model that can be simply employed to develop a VAP prevention program are as follows: Stages Plan: 1. Identify potentially modifiable risk factors for VAP at the institutional level. 2. Develop a strategy to modify or prevent the occurrence of these risk factors. [figure: see text] Do: 1. Carry out the planned intervention strategy. 2. Identify problems in the implementation of the designed intervention. 3. Update the intervention with solutions for the identified problems. 4. Collect basic data (e.g., VAP rates, severity of illness). STUDY: 1. Analyze data. 2. Summarize the results. Act: 1. Determine the overall success or failure of the intervention. 2. Identify potential modifications to improve the intervention strategy. 3. Prepare for next PDSA cycle. Inherent in the development and application of such programs is the concept that they are continuous processes striving to improve clinical performance over time (Fig. 3). At any given institution, the most likely approach to the prevention of NP and VAP will be a multifaceted one, employing interventions aimed at reducing the occurrence of aerodigestive tract colonization with pathogenic bacteria and aspiration. To be successful, such quality improvement programs must be embraced at the institutional level. Only in this way can hospitals hope to successfully reduce their rates of VAP and sustain or improve upon those efforts over time.

Entities:  

Mesh:

Year:  1999        PMID: 10516910     DOI: 10.1016/s0272-5231(05)70242-2

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  7 in total

Review 1.  Silver-coated endotracheal tubes for prevention of ventilator-associated pneumonia in critically ill patients.

Authors:  George Tokmaji; Hester Vermeulen; Marcella C A Müller; Paulus H S Kwakman; Marcus J Schultz; Sebastian A J Zaat
Journal:  Cochrane Database Syst Rev       Date:  2015-08-12

2.  Ventilator-associated pneumonia: caveats for benchmarking.

Authors:  Philippe Eggimann; Stéphane Hugonnet; Hugo Sax; Sylvie Touveneau; Jean-Claude Chevrolet; Didier Pittet
Journal:  Intensive Care Med       Date:  2003-09-03       Impact factor: 17.440

3.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

4.  Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells.

Authors:  Gregory B Pott; K Scott Beard; Courtney L Bryan; Daniel T Merrick; Leland Shapiro
Journal:  Front Public Health       Date:  2013-06-21

Review 5.  Nosocomial pneumonia : rationalizing the approach to empirical therapy.

Authors:  Gunnar I Andriesse; Jan Verhoef
Journal:  Treat Respir Med       Date:  2006

6.  Costs and risk factors for ventilator-associated pneumonia in a Turkish university hospital's intensive care unit: a case-control study.

Authors:  Riza Hakan Erbay; Ata Nevzat Yalcin; Mehmet Zencir; Simay Serin; Habip Atalay
Journal:  BMC Pulm Med       Date:  2004-04-26       Impact factor: 3.317

Review 7.  Prevention of ventilator-associated pneumonia in the intensive care unit: a review of the clinically relevant recent advancements.

Authors:  Holly Keyt; Paola Faverio; Marcos I Restrepo
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.